| Methylprednisolone | Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | Phase 2 | Active not recruiting | 7 | Feb 2027 |
| Abemaciclib | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Active not recruiting | 45 | Feb 2027 |
| tirzepatide | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active not recruiting | 905 | Nov 2026 |
| tirzepatide | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active not recruiting | 465 | Nov 2026 |
| Baricitinib 4 milligram Oral Tablet | Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study | Phase 2 | Completed | 10 | Aug 12, 2026 |
| Retatrutide | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Phase 3 | Active not recruiting | 1,250 | Aug 2026 |
| Orforglipron | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Phase 3 | Completed | 712 | Jul 21, 2026 |
| tirzepatide | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Phase 2 | Completed | 134 | Jul 6, 2026 |
| tirzepatide | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Phase 2 | Completed | 367 | Jul 1, 2026 |
| Mirikizumab | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) | Phase 3 | Active not recruiting | 1,063 | Jul 2026 |
| Retatrutide | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Phase 3 | Completed | 1,152 | Jun 16, 2026 |
| tirzepatide | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Phase 2 | Completed | 12 | Jun 2, 2026 |
| Taltz | Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis | Phase 2 | Completed | 10 | May 19, 2026 |
| Lebrikizumab | A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis | Phase 3 | Completed | 221 | May 13, 2026 |
| Ramucirumab | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed · results | 43 | May 11, 2026 |
| Mevidalen | A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | Phase 2 | Completed | 304 | May 1, 2026 |
| Mirikizumab IV | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis | Phase 3 | Completed | 63 | May 1, 2026 |
| Abemaciclib, | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Phase 2 | Completed | 14 | Apr 30, 2026 |
| Baricitinib | Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent | Phase 2 | Completed | 27 | Apr 28, 2026 |
| Lebrikizumab | Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis | Phase 3 | Completed | 174 | Apr 23, 2026 |
| Retatrutide | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Phase 3 | Completed | 1,946 | Apr 16, 2026 |
| tirzepatide | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes | Phase 3 | Completed | 150 | Apr 13, 2026 |
| Retatrutide | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Phase 3 | Completed | 2,335 | Apr 6, 2026 |
| Baricitinib | Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease | Phase 2 | Completed | 8 | Apr 3, 2026 |
| Mazdutide | A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Phase 2 | Completed | 308 | Mar 19, 2026 |
| Orforglipron | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | Phase 3 | Completed | 2,749 | Mar 16, 2026 |
| Fulvestrant | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | Phase 2 | Completed · results | 27 | Mar 12, 2026 |
| Abemaciclib | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | Phase 2 | Terminated · results | 6 | Mar 11, 2026 |
| tirzepatide | Tirzepatide for Obesity and Meth Use Disorder | Phase 2 | Completed | 35 | Feb 12, 2026 |
| Retatrutide | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | Phase 3 | Completed | 537 | Jan 22, 2026 |
| tirzepatide | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | Completed | 441 | Jan 20, 2026 |
| LY3848575 | Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy | Phase 2 | Completed | 558 | Jan 12, 2026 |
| tirzepatide | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Phase 3 | Completed | 281 | Jan 8, 2026 |
| LY3549492 | A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight | Phase 2 | Completed | 288 | Jan 7, 2026 |
| tirzepatide | A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Phase 2 | Completed | 392 | Dec 15, 2025 |
| LY3871801 | An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Phase 2 | Completed | 164 | Dec 8, 2025 |
| Lasmiditan | A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | Phase 3 | Terminated · results | 558 | Dec 4, 2025 |
| tirzepatide | Effect of Tirzepatide on Brown Adipose Tissue in Obesity | Phase 2 | Completed | 34 | Nov 29, 2025 |
| Orforglipron | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Phase 3 | Completed | 376 | Nov 21, 2025 |
| tirzepatide | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Phase 3 | Completed | 279 | Nov 18, 2025 |